Home > News > Pharmaceutical News

Venus launches nano-emulsion for arthritic pain

Posted on Aug 22, 02:58PM | IBNS

Venus Remedies Limited, (BSE Code-526953) a research based global pharmaceutical company, on Wednesday said it has launched for the first time a research based product "TROIS" in the Indian markets. This patent protected topical nano-emulsion is developed by using the integrated natural medicine approach to relieve from all kind of arthritic pain.

Talking about the product, Dr. Manu Chaudhary, Joint Managing Director and Director- Research, Venus Remedies Limited, said: "The problem of Arthritis is a constantly growing epidemic in India. As per the latest reports, almost 15pc of the Indian population is suffering with this crippling disease.

"We felt the pressing need to develop an alternative solution for rheumatic disorders and related infections, thus have come up for the first time with a topical nano emulsion "TROIS" to relieve the Arthritic pain."

At present, there are many biological products available in the markets for treating arthritis and related condition, but they have many side effects associated with them.

Prevalent treatment of Rheumatoid diseases includes drugs such as non-steroidal, anti inflammatory drugs (NSAIDS), corticosteroids, slow acting anti-rheumatic drugs (SAARDS) or disease modifying (DM) drugs include penicillin amine like drugs such as cyclophosphamide, methotrexate, gold salts, azothioprine, levamisole and the like.

All these drugs have severe side effects and most of them are cytotoxic, said the company.

Trois is the most effective drug for the treatment of Arthritis and is getting outstanding response in the various markets across India.

As per Dheeraj Aggarwal, CFO, Venus Remedies Limited, "With the kind of response we are getting for this revolutionary nano tech emulsion in pain management as topical pain killer in arthritis, we are hopeful of capturing a significant share of the rheumatoid arthritis drug market in India, which is speculated to grow up to USD 672 million in 2013."

"We have already filed patents for TROIS in the major markets across the globe and based on the regulatory approvals, we are soon going the launch our products in the international markets as well," he said.

Trois is indicated for the treatment of Pain and Inflammation as associated with Osteoarthritis, Rheumatoid arthritis, Juvenile idiopathic arthritis, Gouty arthritis, Ankylosing spondylitis, Psoriatic arthritis, Backache, Sprain and fibromyalgia.